In particular, studies on the association of intermediate repeat expansions with the clinical features of ALS or disease progression could pave the way for refining individual prognostic predictions and improving ALS clinical trial design, as is already happening with ATXN2. Here, ATXN2 is linked to amyotrophic lateral sclerosis.